Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70382 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Sujit Sheth und 25 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: beta-Thalassemia, Erythropoiesis, Iron. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vertex Pharmaceuticals, CRISPR Therapeutics.
Abstract (Originalsprache)
Exagamglogene autotemcel (exa‐cel) is a one‐time, ex vivo, CRISPR‐Cas9 gene edited cell therapy approved for patients with transfusion dependent β‐thalassemia (TDT) aged 12–35 years. In a Phase 3 study (CLIMB THAL‐111), exa‐cel treatment resulted in reactivation of fetal hemoglobin and increases in total hemoglobin, leading to transfusion independence in 91% of participants. Here, we report on the impact of exa‐cel treatment on measures of ineffective erythropoiesis and iron homeostasis, which were secondary and exploratory endpoints in CLIMB THAL‐111 and the CLIMB‐131 long‐term follow‐up study. Prior to exa‐cel infusion, all participants were receiving regular red blood cell transfusions and iron chelation therapy. At time of data cut (April 2025), 98% of participants (55 of 56) had been transfusion independent for ≥ 12 months and 38 (68%) had discontinued iron removal therapy (mean duration off iron removal therapy 19.4 months). Following transfusion independence and cessation of iron removal therapy, erythroferrone concentrations decreased and hepcidin levels normalized in all participants, indicating correction of ineffective erythropoiesis and restoration of iron homeostasis. Further supporting this finding, improvements and trends toward normalization were seen in key erythropoiesis biomarkers, including erythropoietin levels, reticulocyte counts, and soluble transferrin receptor concentrations. Iron overload biomarkers, including ferritin, liver iron concentration, and cardiac T2*, decreased and then remained stable throughout follow‐up, even after cessation of iron removal therapy. These results demonstrate restoration of effective erythropoiesis and iron homeostasis after exa‐cel infusion in the setting of transfusion independence following reactivation of fetal hemoglobin. (CLIMB THAL‐111 and CLIMB‐131; Clinical Trials.gov numbers NCT03655678 and NCT04208529).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Weill Cornell Medicine, New York, New York, USA.
- University of Regensburg, Regensburg, Germany.
- Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.
- IRCCS, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
- Department of Health Sciences, Magna Graecia University, Catanzaro, Italy.
- University Children's Hospital Tübingen, Tübingen, Germany.
ORCID-Profile: Sujit Sheth, Yogi Chopra, Antonis Kattamis, Franco Locatelli
Förderung
- Vertex Pharmaceuticals
- CRISPR Therapeutics
Zitieren
APA
Sheth, S., Corbacioglu, S., de la Fuente, J., Algeri, M., Rupprecht, J., Kuo, K. H. M., Shah, A. J., Lang, P., Merkeley, H., Carpenter, B., Mapara, M. Y., Liem, R. I., Grupp, S., Chopra, Y., Li, A. M., Kwiatkowski, J. L., Kirby-Allen, M., Cappellini, M. D., Kattamis, A., …, & CLIMB THAL‐111 and CLIMB‐131 Study Groups (2026). Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia. American Journal of Hematology. https://doi.org/10.1002/ajh.70382
Vancouver
Sheth S, Corbacioglu S, de la Fuente J, Algeri M, Rupprecht J, Kuo KHM, et al. Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia. American Journal of Hematology. 2026. doi:10.1002/ajh.70382
BibTeX
@article{Sheth2026,
author = {Sheth, Sujit and Corbacioglu, Selim and de la Fuente, Josu and Algeri, Mattia and Rupprecht, Joachim and Kuo, Kevin H M and Shah, Ami J and Lang, Peter and Merkeley, Hayley and Carpenter, Ben and Mapara, Markus Y and Liem, Robert I and Grupp, Stephan and Chopra, Yogi and Li, Amanda M and Kwiatkowski, Janet L and Kirby-Allen, Melanie and Cappellini, Maria Domenica and Kattamis, Antonis and Zairis, Sakellarios and Liu, Tina and Hobbs, William and Frangoul, Haydar and Locatelli, Franco and Meisel, Roland and CLIMB THAL‐111 and CLIMB‐131 Study Groups, CLIMB THAL‐111 and CLIMB‐131 Study Groups},
title = {Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70382}
}
EUVIMED